about
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsHepatitis C virus immune escape via exploitation of a hole in the T cell repertoireImmunotherapy in acute leukemiaInduction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationCyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigenMolecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progressionActivation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Inducible T-cell receptor expression in precursor T cells for leukemia control.Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.Hunting for clinical translation with innate-like immune cells and their receptors.WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms.Differential expression of THELPER 1 cytokines upon antigen stimulation predicts ex vivo proliferative potential and cytokine production of virus-specific T cells following re-stimulation.Selective modification of antigen-specific T cells by RNA electroporation.Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.Enumeration of WT1-specific CD8(+) T cells for clinical application using an MHC Streptamer based no-wash single-platform flow-cytometric assay.Functional characterization of Foxp3-specific spontaneous immune responses.
P2860
Q27026836-041E5B72-F3F9-4D83-AF98-C6ED092AC0BFQ27489598-026995D0-D510-4DCC-8BC8-0091F0CD5046Q33731552-74C920AB-9A1C-46D0-A9FC-DC20B5E1B0E5Q34068404-F002B02D-9C23-4FE8-A6B1-5296F23D38EAQ34243434-279FF04E-438B-43A3-8EF6-2199BB53FBEFQ34955908-7B18B7AA-E1D0-4447-A0B6-EA2E14FB7925Q35698863-D4694387-71D2-4DD8-8A80-EAC2EC71E4C7Q35850673-05ABDD8B-63CD-4A9F-A9DC-807F1ED91515Q35921900-8DB4017C-BEF8-463D-8111-857CB0869697Q36107961-3AAA6879-0B41-4BE4-A451-C5FD821C0885Q36166038-68BB97AA-6B5A-460F-936B-5957432407AEQ36694195-A0A881E7-BA90-4226-8E70-D8566CE97BC3Q38171917-6FF38F28-AC3C-40D9-837D-CEBA1960A062Q39862474-7F38AD3F-54C3-4701-AAD9-DA1A099F59E1Q40296275-9730E2BD-E1BB-4E21-9FD0-FB33A3C807DBQ40504861-AA610293-B721-4F98-BCA9-BB6663F14EEFQ41748023-CE5B35CC-C9A7-48BA-9CA6-381339E42648Q42321216-F32F4F06-8197-4E0C-AE52-EE3BAA791F1DQ42609684-2A6CE2A9-D3B9-4F64-A8EF-44F9278937FCQ45415157-CF4D776F-C86B-4F88-9741-1537670B4172Q48644166-CD6275F9-FB13-49E3-90ED-11EF2CF7ED1CQ50868528-8A390B43-211C-4801-AE3D-3588B7061BCE
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antigen-specific cellular immunotherapy of leukemia.
@ast
Antigen-specific cellular immunotherapy of leukemia.
@en
type
label
Antigen-specific cellular immunotherapy of leukemia.
@ast
Antigen-specific cellular immunotherapy of leukemia.
@en
prefLabel
Antigen-specific cellular immunotherapy of leukemia.
@ast
Antigen-specific cellular immunotherapy of leukemia.
@en
P2093
P2860
P356
P1433
P1476
Antigen-specific cellular immunotherapy of leukemia
@en
P2093
Berneman ZN
Van Bockstaele DR
Van Driessche A
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403930
P577
2005-11-01T00:00:00Z